PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
19-Jan-2024 MediClin AG: MediClin AG
19-Jan-2024 Biovica Signs Agreement with Palex Group, a Market Leader in Spain and Portugal AccessWire
19-Jan-2024 Ace Neuroscience Unveils Antipsychotic Drug Development to Boost Mental Illness Research Ace Neuroscience
19-Jan-2024 Amerigo Scientific Released A Well-Selection ELISA Kits Featured with Simplicity and Consistency Amerigo Scientific
19-Jan-2024 Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium AccessWire
18-Jan-2024 De Oro Devices Names Cori Lathan, PhD, as New CEO AccessWire
18-Jan-2024 CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China AccessWire
18-Jan-2024 HemoFlow 500 Series, the Next Generation Blood Scale/Mixer Devices, Launch in the United States Market AccessWire
18-Jan-2024 Mercy Health and the City of Mason Celebrate Grand Opening of New Mercy Health-Kings Mills Hospital AccessWire
18-Jan-2024 Metrodora Foundation Announces New Scientific Advisory Board AccessWire
18-Jan-2024 Kromek receives $1.6m in advanced imaging orders Kromek
18-Jan-2024 Verseon Gain US Patent Protection for Compounds that Could Eliminate Bleeding Risks of Current Anticoagulants Verseon
18-Jan-2024 Kindeva Drug Delivery Acquires Summit Biosciences, a Specialized Nasal Drug Development and Manufacturing Organization Kindeva Drug Delivery
18-Jan-2024 Aptar Digital Health and Moffitt Cancer Center Launch Clinical Evaluation for Oncology Digital Therapeutic, Oleena® Aptar Digital Health
18-Jan-2024 Onyx Scientific Targets Stateside Expansion with New Appointment Onyx
18-Jan-2024 More Than 350 Companies Increase Efficiency and Compliance with Veeva Training Solutions Veeva
18-Jan-2024 Peptide-Pilot offers revolution in drug development cycle times Vapourtec
18-Jan-2024 Strengthened footprint for OPTIMA project in Scandinavia OPTIMA
18-Jan-2024 Oxford BioTherapeutics Announces First Patient Dosed with OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck Oxford BioTherapeutics
18-Jan-2024 Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510 Synendos Therapeutics